Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter M Stadler

Showing results (1-10 of 241) with videos related to

Pageof 25
Sort By:
Oncology (Williston Park, N.Y.)|May 2, 2012
Renal cancer therapeutics: now what?Walter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
New targets, therapies, and toxicities: lessons to be learnedWalter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Maturing of renal cancer therapeuticsWalter M Stadler
Journal of Oncology Practice|August 13, 2019
Management of Urothelial Bladder Cancer: Predicting the FutureWalter M Stadler
BJU International|July 11, 2006
Development of growth inhibitory agents in urological and other malignanciesWalter M Stadler
Molecular Cancer Therapeutics|April 14, 2007
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agentsWalter M Stadler
Cancer|August 7, 2009
Prognosis and prediction in a Facebook worldWalter M Stadler
Seminars in Oncology|March 15, 2002
Gemcitabine doublets in advanced urothelial cancerWalter M Stadler
Der Urologe. Ausg. A|May 28, 2004
Cytotoxic chemotherapy for metastatic renal cell carcinomaWalter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Effective therapy for metastatic renal cancer, whither to nowWalter M Stadler
Pageof 25

Showing results (1-10 of 241) with videos related to

Sort By:
Pageof 25
Oncology (Williston Park, N.Y.)|May 2, 2012
Renal cancer therapeutics: now what?Walter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
New targets, therapies, and toxicities: lessons to be learnedWalter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Maturing of renal cancer therapeuticsWalter M Stadler
Journal of Oncology Practice|August 13, 2019
Management of Urothelial Bladder Cancer: Predicting the FutureWalter M Stadler
BJU International|July 11, 2006
Development of growth inhibitory agents in urological and other malignanciesWalter M Stadler
Molecular Cancer Therapeutics|April 14, 2007
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agentsWalter M Stadler
Cancer|August 7, 2009
Prognosis and prediction in a Facebook worldWalter M Stadler
Seminars in Oncology|March 15, 2002
Gemcitabine doublets in advanced urothelial cancerWalter M Stadler
Der Urologe. Ausg. A|May 28, 2004
Cytotoxic chemotherapy for metastatic renal cell carcinomaWalter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Effective therapy for metastatic renal cancer, whither to nowWalter M Stadler
Pageof 25